Moderna’s first mRNA-based protein replacement therapy passed early clinical trials
- FDA Approved Opdualag: The First Immunotherapy Targeting LAG-3
- Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Evidence
- Brief Intermittent Exercise Reduces Heart Disease and Death Risk
- Personalized Lung Tumor Chips Assess PD-1 Therapy Response
- Study Shows Prior Infection Offers Strong Immunity to Original COVID-19 Strain
- Chinese Food Products Dominate Korean Tables Amid Safety Concerns
Moderna’s first mRNA-based protein replacement therapy passed early clinical trials
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Moderna’s first mRNA-based protein replacement therapy passed early clinical trials
Moderna , which has achieved great commercial success with its mRNA COVID-19 vaccine , is actively exploring the application of mRNA beyond vaccines, including mRNA-based gene editing therapy, cell therapy, and representative replacement therapy .
Since the company was founded, Moderna has set the goal of transforming human cells into drug production factories. By hijacking cellular mechanisms, cells in the body can produce therapeutic molecules by themselves. Moderna hopes to deliver mRNA to cells in this way. , for protein replacement therapy.
On May 19, 2023, Moderna reported for the first time at the 2023 American Society for Gene + Cell Therapy Annual Meeting (ASGCT) the Phase 1/2 clinical trial data of its mRNA – 3927 therapy , which is encapsulated by lipid nanoparticles Two mRNAs encode two protein subunits PCCA and PCCB, respectively, to synthesize propionyl-CoA carboxylase (PCC) for the treatment of propionic acidemia (Propionic Acidemia, PA) .
Propionic acidemia (PA) is a rare autosomal recessive genetic disease. Due to the mutation of PCCA or PCCB gene, the activity of propionyl-CoA carboxylase (PCC) encoded by it is lost, resulting in the loss of propionate and its metabolites in the body. Abnormal accumulation can cause metabolic acidosis, high blood ammonia, brain damage and multiple organ damage.
The phase 1/2 clinical trial showed early signs of efficacy, with many patients who had potentially life-threatening metabolic dysregulation events before receiving mRNA therapy , and their incidence of metabolic dysregulation events was significantly reduced after receiving treatment , The risk of metabolic dysregulation was reduced by 66% overall and by 78% in the four cohorts treated with one injection every two weeks .
This suggests that mRNA technology could treat propionic acidemia by replacing the protein in cells .
Kyle Holen , M.D. , director of development, therapeutics and oncology at Moderna, said that as the clinical trial enters the dose expansion phase, we continue to observe encouraging results for mRNA-3927, and we will further evaluate safety, efficacy, and determine future Recommended dosage in clinical studies. So far, we have treated more than 13 patients for more than one year.
Paper link :
https://investors.modernatx.com/news/news-details/2023/Phase-12-Interim-Data-on-Modernas-mRNA-3927-an-Investigational-mRNA-Therapy-for-Propionic-Acidemia-PA- Presented-at-the-2023-ASGCT-Annual-Meeting/default.aspx
Moderna’s first mRNA-based protein replacement therapy passed early clinical trials
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.